References
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
- Tamayo S, Frank Peacock W, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27,467 patients taking rivaroxaban. Clin Cardiol 2015;38:63-8
- Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2015: published online 1 September 2015, doi:10.1093/eurheartj/ehv466
- Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857
- Maura G, Blotière PO, Bouillon K, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 2015;132:1252-60
- Engelberger RP, Noll G, Schmidt D, et al. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: The Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study. Eur J Intern Med 2015;26:508-14
- Coleman CI, Antz M, Ehlken B, Evers T. REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation – The RELIEF study. Int J Cardiol 2016;203:882-4
- Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955-62
- Laliberté F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-25
- Ogawa S, Ikeda T, Kitazono T, et al. Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry. J Stroke Cerebrovasc Dis 2014;23:2520-06
- NHS Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness: CRD’s Guidance for Those Carrying Out or Commissioning Reviews. Report number 4 (2nd edition). York: CRD, 2001
- Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219
- Lip GY, Pan X, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin (abstract). Eur Heart J 2015;36:1085